Compare Bristol-Myers Squibb Co (BMY) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Petróleo Brasileiro SA — how do they compare? Bristol-Myers Squibb Co trades at $58.94 (market cap $116.30B), while Petróleo Brasileiro SA trades at $17.83 (market cap $108.05B). The key difference: Bristol-Myers Squibb Co and Petróleo Brasileiro SA are close in size by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.84%). Which is the better fit depends on your goals.
| BMY | PBR | |
|---|---|---|
Market Cap | $116.30B | $108.05B |
Sector | Health | Technology |
52-Week High | $62.37 | $22.03 |
52-Week Low | $42.60 | $11.54 |
Enterprise Value | $152.24B | $170.59B |
Dividend Yield | 4.42% | 9.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
PBR trades at $17.88, up 3.23% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 5.71, net income margin of 21.47%, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments, supporting growth prospects amid positive analyst sentiment.
Outlook remains favorable with a consensus price target of $23.90, representing 33.6% upside potential. Key risks include oil price volatility and execution of new projects. The combination of low valuation, robust cash flow, and strategic expansion provides a compelling case for long-term investors, though market fluctuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
